文献速递介入腹部US

尾状叶肝细胞癌治疗:超声引导经皮射频消融联合乙醇消融

Treatment of hepatocellular carcinoma in the caudate lobe: US-guided percutaneous radiofrequency ablation combined with ethanol ablation.
PubMed 文献 · Clin Radiol · 2018-04-04

回顾性研究纳入14例尾状叶肝细胞癌患者(16个病灶),行超声引导经皮射频消融联合乙醇消融,并与射频消融单独组(17例)和乙醇消融单独组(18例)比较。联合组全部获得治疗成功,1年和2年局部肿瘤进展率分别为18.8%和27.8%,1年和2年无病生存率分别为35.7%和13.4%,1年、2年和3年总生存率分别为85.1%、63.1%和21%。三组间局部肿瘤进展、无病生存和总生存率无显著差异。结论认为联合治疗对尾状叶肝细胞癌似乎是可行且有效的。

要点

  • 超声引导经皮射频消融联合乙醇消融治疗尾状叶肝细胞癌全部14例获得治疗成功。
  • 联合组1年和2年局部肿瘤进展率分别为18.8%和27.8%。
  • 联合组与射频消融单独组或乙醇消融单独组在局部肿瘤进展、无病生存和总生存率上无显著差异。

核心结论

  • 超声引导经皮射频消融联合乙醇消融对尾状叶肝细胞癌似乎是可行且有效的治疗方法。

研究设计与样本

  • 回顾性研究,经机构审查委员会批准并豁免知情同意,2009年10月至2016年6月共49例尾状叶肝细胞癌患者接受消融治疗。
  • 联合组14例患者(12男2女,平均年龄49.9±14.9岁)共16个尾状叶肝细胞癌病灶(平均大小3±1.1 cm),行超声引导射频消融联合乙醇消融。
  • 对照组为射频消融单独组(n=17)和乙醇消融单独组(n=18)。

诊断标准与关键数值

  • 联合组病灶大于乙醇消融单独组(3±1.1 cm vs 2.1±0.7 cm,p=0.028)。
  • 联合组全部患者获得治疗成功(14/14)并进入随访,随访时间17.1±10.6个月(范围5-36个月)。
  • 联合组1年和2年局部肿瘤进展率分别为18.8%和27.8%。
  • 联合组1年和2年无病生存率分别为35.7%和13.4%。
  • 联合组1年、2年和3年总生存率分别为85.1%、63.1%和21%,6例患者死亡。

临床应用与阅片要点

  • 作者认为超声引导经皮射频消融联合乙醇消融对尾状叶肝细胞癌似乎是可行且有效的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate the technical feasibility and treatment results of ultrasound (US)-guided percutaneous radiofrequency ablation (RFA) combined with ethanol ablation (EA) for hepatocellular carcinoma (HCC) in the caudate lobe.

MATERIALS AND METHODS: The institutional review board approved this retrospective study and the requirement for informed consent was waived. From October 2009 to June 2016, there were 49 patients with HCC in the caudate lobe underwent ablation. Among them, 14 patients (12 men and two women, mean age: 49.9±14.9 years) with 16 caudate lobe HCCs (mean size: 3±1.1 cm) who underwent US-guided RFA-EA were identified. These patients were compared with patients who underwent RFA alone (n=17) and EA alone (n=18).

RESULTS: HCCs in the RFA-EA group were larger than those in the EA-alone group (3±1.1 versus 2.1±0.7 cm, p=0.028). In the RFA-EA group, all the patients achieved treatment success (14/14) and entered follow-up. After a follow-up period of 17.1±10.6 months (range, 5-36 months), local tumour progression (LTP) was detected in four tumours. The 1- and 2-year LTP rates after RFA-EA were 18.8% and 27.8%, respectively. The 1- and 2-year disease-free survival (DFS) rates were 35.7% and 13.4%. Six patients died, with the 1-, 2-, and 3-year overall survival (OS) rates of 85.1%, 63.1%, and 21%, respectively. There were no significant differences in the LTP, DFS, and OS rates between the RFA-EA group and RFA-alone or EA groups (p=0.363-0.733).

CONCLUSION: US-guided percutaneous RFA-EA appears to be a feasible and effective treatment for HCC in the caudate lobe.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Liu B, Long J, Wang W, et al. Treatment of hepatocellular carcinoma in the caudate lobe: US-guided percutaneous radiofrequency ablation combined with ethanol ablation. Clin Radiol. 2018. PMID: 29627066. doi:10.1016/j.crad.2018.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。